CO4940454A1 - NEW METHOD OF TREATMENT - Google Patents

NEW METHOD OF TREATMENT

Info

Publication number
CO4940454A1
CO4940454A1 CO98034654A CO98034654A CO4940454A1 CO 4940454 A1 CO4940454 A1 CO 4940454A1 CO 98034654 A CO98034654 A CO 98034654A CO 98034654 A CO98034654 A CO 98034654A CO 4940454 A1 CO4940454 A1 CO 4940454A1
Authority
CO
Colombia
Prior art keywords
treatment
insulin
mammal
new method
compound
Prior art date
Application number
CO98034654A
Other languages
Spanish (es)
Inventor
Smith Stephen Alistair
Original Assignee
Smithkline Beecham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham filed Critical Smithkline Beecham
Publication of CO4940454A1 publication Critical patent/CO4940454A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método para el tratamiento de diabetes mellitus y procesosasociados a la diabetes mellitus en un mamífero, cuyo método comprende administrar una cantidad eficaz, no tóxica y farmacéuticamente aceptable de 5-[4-[2-(N-metil-N-2-piridil)amino)etoxilbencil]tia-zolidin-2,4-diona [aquí en lo sucesivo ´Compuesto (I)´l e insulina a un mamífero con necesidad de ello. 1Una composición farmacéutica, que comprende Compuesto (I), insulina y un vehículo farmacéuticamente aceptable para los mismos.A method for the treatment of diabetes mellitus and processes associated with diabetes mellitus in a mammal, the method of which comprises administering an effective, non-toxic and pharmaceutically acceptable amount of 5- [4- [2- (N-methyl-N-2-pyridyl ) amino) ethoxybenzyl] thia-zolidin-2,4-dione [hereinafter 'Compound (I)' insulin to a mammal in need thereof. 1A pharmaceutical composition, comprising Compound (I), insulin and a pharmaceutically acceptable carrier therefor.

CO98034654A 1997-06-18 1998-06-18 NEW METHOD OF TREATMENT CO4940454A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
CO4940454A1 true CO4940454A1 (en) 2000-07-24

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98034654A CO4940454A1 (en) 1997-06-18 1998-06-18 NEW METHOD OF TREATMENT

Country Status (30)

Country Link
EP (1) EP0999837A1 (en)
JP (1) JP2002504138A (en)
KR (1) KR20010013843A (en)
CN (1) CN1133431C (en)
AP (1) AP1287A (en)
AR (2) AR012997A1 (en)
AU (1) AU8216398A (en)
BG (1) BG104059A (en)
BR (1) BR9810444A (en)
CA (1) CA2294141A1 (en)
CO (1) CO4940454A1 (en)
DZ (1) DZ2521A1 (en)
EA (1) EA004800B1 (en)
GB (1) GB9712866D0 (en)
HU (1) HUP0003260A3 (en)
ID (1) ID23951A (en)
IL (1) IL133143A0 (en)
IN (1) IN189723B (en)
MA (1) MA26511A1 (en)
NO (1) NO996265L (en)
OA (1) OA11517A (en)
PE (1) PE104499A1 (en)
PL (1) PL343123A1 (en)
SK (1) SK179399A3 (en)
TR (1) TR199903095T2 (en)
TW (1) TW587937B (en)
UA (1) UA70299C2 (en)
UY (1) UY25050A1 (en)
WO (1) WO1998057636A1 (en)
ZA (1) ZA985237B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
TR200103061T2 (en) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. New pharmaceutical ingredient.
WO2000078333A2 (en) 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
MXPA05004743A (en) 2002-11-08 2005-08-03 Hoffmann La Roche Substituted 4-alkoxyoxazol derivatives as ppar agonists.
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (en) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 Solid oral preparation containing rosiglitazone and cetirizine hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719140B1 (en) * 1993-09-15 2007-10-31 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
KR19990045756A (en) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 NIDDM treatment using RXR agonists

Also Published As

Publication number Publication date
TW587937B (en) 2004-05-21
PL343123A1 (en) 2001-07-30
CN1260715A (en) 2000-07-19
AU8216398A (en) 1999-01-04
SK179399A3 (en) 2000-11-07
EA004800B1 (en) 2004-08-26
BR9810444A (en) 2000-09-05
CA2294141A1 (en) 1998-12-23
CN1133431C (en) 2004-01-07
KR20010013843A (en) 2001-02-26
AP1287A (en) 2004-06-26
AP9901718A0 (en) 1999-12-31
NO996265D0 (en) 1999-12-17
ID23951A (en) 2000-06-08
NO996265L (en) 1999-12-17
UY25050A1 (en) 2000-09-29
BG104059A (en) 2000-10-31
WO1998057636A1 (en) 1998-12-23
IN189723B (en) 2003-04-19
OA11517A (en) 2004-02-04
HUP0003260A3 (en) 2001-12-28
AR012997A1 (en) 2000-11-22
MA26511A1 (en) 2004-12-20
HUP0003260A2 (en) 2001-05-28
ZA985237B (en) 2000-02-17
EP0999837A1 (en) 2000-05-17
JP2002504138A (en) 2002-02-05
GB9712866D0 (en) 1997-08-20
DZ2521A1 (en) 2003-02-08
AR015894A1 (en) 2001-05-30
PE104499A1 (en) 2000-01-13
IL133143A0 (en) 2001-03-19
UA70299C2 (en) 2004-10-15
TR199903095T2 (en) 2000-08-21
EA200000042A1 (en) 2000-08-28

Similar Documents

Publication Publication Date Title
CO4940454A1 (en) NEW METHOD OF TREATMENT
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
YU37301A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
EA200000139A1 (en) TREATMENT OF DIABETES THIAZOLIDINDIONON, MEANS, INCENTIVE INSULIN SECRETION, AND DIGUANIDE
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
AR008198A1 (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION OF 5- [4- [2- (N- METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIN-2,4-DIONA
PE108199A1 (en) PHARMACEUTICAL COMPOSITION OF TIAZOLIDINDIONA AND SULFONILUREA
AR016350A1 (en) USE OF AN INSULIN SENSITIZER, AN INSULIN SECRETAGOG AND AN ALFA-GLUCOSIDASE INHIBITING ANTI-HERITAGE AGENT TO PREPARE MEDICATIONS
AR016768A1 (en) PHARMACEUTICAL COMPOSITION OF 5- (4- (2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI) BENCIL) TIAZOLIDIN-2-4-DIONA AND AN INSULIN SECRETAGOG AND THE SAME FOR MEDICINAL PREPARATION
AR013352A1 (en) USE OF AN INSULIN SENSITIZER AND AN ANTI-HYPERGLYCEMIC AGENT FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF DIABETES MELLITUS AND CONDITIONS ASSOCIATED WITH IT AND A PHARMACEUTICAL COMPOSITION.
CO5150180A1 (en) NEW COMPOSITION AND USE MODIFIED RELEASE
ECSP982542A (en) NEW METHOD OF TREATMENT III
ECSP982593A (en) NEW METHOD OF TREATMENT VI
EA200300423A1 (en) TIAZOLIDINDION DERIVATIVE AND ITS APPLICATION AS AN ANTI-DIABETIC MEDICINE
ECSP982591A (en) NEW METHOD OF TREATMENT IV
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
ECSP982534A (en) NEW METHOD OF TREATMENT
ECSP982592A (en) NEW METHOD OF TREATMENT V
ECSP982535A (en) NEW TREATMENT METHOD (I)